Public, Academic Labs Press FDA To Be Flexible In LDT Requirements
This article was originally published in The Gray Sheet
Executive Summary
State health and academic labs ask FDA to exercise flexibility in its clinical requirements for laboratory-developed tests and warn against unintended consequences for public health testing.
You may also be interested in...
Myriad Enters Companion Diagnostics Field With An FDA First
Myriad Genetics' BRCA1/2 gene testing service has been approved as a companion diagnostic to AstraZeneca's new ovarian cancer drug, an important step in the company's diversification plan and a significant milestone in FDA's oversight of laboratory-developed tests.
Clinical Labs Lawyer Up In Battle Over LDTs
ACLA has recruited Laurence Tribe and Paul Clement, two prominent constitutional legal guns with Supreme Court expertise, to fight FDA over its proposed lab-developed test guidance. The announcement is perhaps the lab industry's most high profile move yet to oppose FDA's plan to regulate lab-developed test services under the device statute with a risk-based phase-in plan.
FDA Releases LDT Regulatory Framework, Notification Draft Guidances
Two promised draft guidances on FDA’s framework for regulating laboratory developed tests and notification and medical device reporting requirements for LDTs have been posted. The agency wants swift notification from labs for most available LDTs once a framework is finalized.